California State Teachers Retirement System Rallybio Corp Transaction History

California State Teachers Retirement System

$84.1 Billion
Q3 2024

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.25 - $2.4 $1,950 - $3,744	-1,560 Reduced 31.0%	3,472 $6,000
Q4 2023 Feb 13, 2024	SELL	$1.91 - $4.39 $3,273 - $7,524	-1,714 Reduced 25.41%	5,032 $12,000
Q3 2023 Nov 14, 2023	SELL	$3.37 - $6.16 $11,538 - $21,091	-3,424 Reduced 33.67%	6,746 $22,000
Q2 2023 Aug 21, 2023	BUY	$4.31 - $8.89 $13,684 - $28,225	3,175 Added 45.39%	10,170 $57,000
Q1 2023 May 09, 2023	SELL	$4.37 - $8.75 $1,555 - $3,115	-356 Reduced 4.84%	6,995 $39,000
Q4 2022 Feb 14, 2023	BUY	$4.67 - $14.86 $4,922 - $15,662	1,054 Added 16.74%	7,351 $48,000
Q3 2022 Nov 18, 2022	SELL	$7.54 - $14.56 $3,958 - $7,644	-525 Reduced 7.7%	6,297 $91,000
Q2 2022 Aug 15, 2022	SELL	$6.26 - $13.65 $5,458 - $11,902	-872 Reduced 11.33%	6,822 $52,000
Q1 2022 May 16, 2022	BUY	$6.91 - $15.04 $29,519 - $64,250	4,272 Added 124.84%	7,694 $54,000
Q4 2021 Feb 15, 2022	SELL	$9.3 - $19.91 $4,333 - $9,278	-466 Reduced 11.99%	3,422 $33,000
Q3 2021 Nov 15, 2021	BUY	$10.83 - $23.4 $42,107 - $90,979	3,888 New	3,888 $68,000

Others Institutions Holding RLYB

# of Institutions

Shares Held

31.9M

Call Options Held

Put Options Held

Viking Global Investors LP

4.19M
Shares

$4.15 Million
0.02% of portfolio
Johnson & Johnson New Brunswick, NJ

3.64M
Shares

$3.6 Million
1.36% of portfolio
5 Am Venture Management, LLC San Francisco, CA

3.63M
Shares

$3.59 Million
1.69% of portfolio
New Leaf Venture Partners, L.L.C. New York, NY

3.3M
Shares

$3.27 Million
3.98% of portfolio
Tpg Gp A, LLC Fort Worth, TX

3.03M
Shares

$3 Million
0.08% of portfolio

View Full List

About Rallybio Corp

Ticker RLYB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,132,000
Market Cap $31.8M
Description
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of feta...

More about RLYB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of California State Teachers Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on California State Teachers Retirement System with notifications on news.

Account